Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  PAO Group, Inc.    PAOG


SummaryAll NewsPress ReleasesOfficial PublicationsSector news

PAOG New Updates Toward Penetrating $5.8B Cannabis Pharmaceutical Market Coming This Friday

share with twitter share with LinkedIn share with facebook
09/14/2020 | 02:20pm EDT

Sandusky, Ohio--(Newsfile Corp. - September 14, 2020) - PAO Group, Inc. (OTC Pink: PAOG) today announced an interview of CEO James C. DiPrima on MoneyTV with Donald Baillargeon scheduled for release this Friday, September 18, 2020. DiPrima will discuss the company's latest CBD bio pharma developments in addition to fielding questions on the recently Goldman Small Cap Analyst Research Update that includes target pricing.

Grand View Research projects that the cannabis pharmaceutical market will reach a size of $5.8 billion by 2027.

Last Mr. DiPrima was on MoneyTV he discussed PAOG's partnership with a Contract Research Organization (CRO) and a formal agreement in the works to advance an Investigational New Drug Application (IND) to ultimately achieve Food and Drug Administration (FDA) approval for PAOG's RespRx as a COPD treatment.

The COPD treatment, RespRx, is derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."

MoneyTV with Donald Baillargeon is the internationally syndicated television program all about money and what makes it happen, featuring informative interviews with company CEOs and executives, providing insights into their operations and outlooks for their futures. MoneyTV is seen in over 200 million TV households in more than 75 countries.

The MoneyTV Interview will be available at www.moneytv.net and will be syndicated across multiple channels and platforms.

Other recent MoneyTV interviews include Singlepoint, Inc. (SING), Surge Holdings, Inc. (SURG), and Halberd, Corp. (HALB).


Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.


Contact Us:
Jim DiPrima

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/63761

© Newsfilecorp 2020
share with twitter share with LinkedIn share with facebook
All news about PAO GROUP, INC.
09/17PAOG Target, CBD Pharma Development, In Puerto Rico Could Get Boost From COVI..
09/16PAOG Announces Agreement to Build Pharmaceutical Hemp Cultivar Facility on PU..
09/15PAOG Advances RespRx Research Into International CBD Pharma Research Arena
09/15PAOG Goes Global with CBD Pharmaceutical Research to Target $5.8 Billion Mark..
09/14PAOG New Updates Toward Penetrating $5.8B Cannabis Pharmaceutical Market Comi..
09/11PURA Announces Analyst Report Pertaining to Coming 1 for 1 Dividend
09/08PAOG Rated Bullish And Given PPS Target In Updated Analyst Report Published T..
09/02PAOG Announces Goldman Small Cap Research Update Scheduled Next Week
More news
Duration : Period :
PAO Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
James C. DiPrima Chief Executive & Financial Officer
Gary C. Bernard Medical Director